Wednesday, February 13, 2013

Dr. Dale Schenk CEO

Prothena Corporation plc

Dr. Dale Schenk, Chief Executive Officer of Prothena, was most recently Chief Scientific Officer and Executive Vice President at Elan Pharmaceuticals where he provided the leadership and scientific direction for Elan’s research and development programs. Prior to joining Elan, Dr. Schenk was a founding scientist of Athena Neurosciences which was acquired by Elan Pharmaceuticals. Dr. Schenk has pioneered the immunotherapeutic approach for the treatment of amyloidosis, as exemplified for Alzheimer’s disease. Dr. Schenk’s work in this area – as well as in early detection, testing and other pathways to the disease – has led to the most advanced potential treatment approaches for Alzheimer’s disease. Dr. Schenk earned his BA and PhD in Pharmacology and Physiology from the University of California, San Diego